Quintrio
Home

BLANK CHECKS

LightWave Acquisition Corp. Class A Ordinary Shares

LWAC

LightWave Acquisition Corp is a blank check company.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $10.41 – $10.41
Volume 11
Market cap $313M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for LWAC.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for LWAC.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Why Is This SPAC Surging 160% Today?

Shares of Locust Walk Acquisition Corp (NASDAQ: LWAC) are surging higher Wednesday morning after the merger with eFFECTOR Therapeutics was approved. eFFECTOR Therapeutics is focused on selective translation regulation inhibitors to treat cancer. The SPAC merger valued the company at $419 million, including a $60 million PIPE with an investment from Pfizer Inc's (NYSE: PFE) venture capital arm Pfizer Ventures. Related Link: Exclusive: Accelerate CEO On SPAC Arbitrage, Why You Can't Always Bet On SPAC Sponsor Why The Stock Is Soaring: Locust Walk Acquisition raised $175 million in its IPO, selling 17.5 ...

Benzinga

EXCLUSIVE: eFFECTOR, Locust Walk Acquisition CEOs On SPAC Deal, Drug Pipeline

Clinical-stage biopharmaceutical company eFFECTOR Therapeutics is set to go public via the special purpose acquisition company Locust Walk Acquisition Corp (NASDAQ: LWAC) with an enterprise value of $419 million. Steve Worland, the president and CEO of eFFECTOR, and Chris Ehrlich, CEO of Locust Walk Acquisition Corp., appeared on Benzinga's YouTube show "SPACs Attack" for an exclusive interview Wednesday. eFFECTOR Programs: eFFECTOR focuses on using a new class of oncology drugs known as selective translation regulation inhibitors to treat cancer. eFFECTOR has a global partnership with Pfizer Inc (NYSE: PFE) for the development of inhibitors of eIF4E, which is the company's earliest stage program, Worland told Benzinga. Tomivosertib, which targets non-small cell lung cancer, is in late-stage Phase 2 trials and is the furthest along of eFFECTOR's programs, he said, adding ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.